Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Kura Oncology, Inc.NASDAQ: KURA
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables falls 72.0% from a year ago
Net receivables stood at $13.65M at the end of Q1 FY2026, down 72.0% from a year earlier and up 8.3% from the prior quarter.
Context
- Net receivables amounted to 2.1% of total assets at the end of Q1 FY2026, down 4.5 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -72.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 12.6M USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.6M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's Mar 2026 net receivables of $13.65M is the 5th highest of the 11 companies compared; the peer median is $5.27M.
- Its year-over-year change of -72.0% is the 7th highest of 8, against a peer median of +20.2%.
- Net receivables amounts to 2.1% of total assets for KURA, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $147.83M | -11.9% | +5.3% | 8.4% | |
| Mar 2026 | $60.69M | +182.5% | +158.8% | 12.8% | |
| Mar 2026 | $49.95M | +20.2% | +8.7% | 9.9% | |
| Aug 2026 | $20M | — | — | 1.7% | |
| Mar 2026 | $13.65M | -72.0% | — | 2.1% | |
| Mar 2026 | $10.36M | +5079.0% | +557.5% | 4.5% | |
| Mar 2026 | $191K | -52.8% | -38.2% | 0.4% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $146K | +265.0% | — | 0.0% |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding KURA) | $5.27M | +20.2% | +8.7% | 1.0% | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 90.67M | 51.8M | 37.32M | 224.46M | 149.1M |
| Short-term Investments | 427.29M | 386.18M | 386.64M | 502.93M | 518.14M |
| Net Receivables | 0 | 0 | 0 | 0 | 12.6M |
| Inventory | 0 | 0 | 0 | 0 | 413K |
| Other Current Assets | 1.4M | 8.44M | 8.52M | 17.43M | 28.41M |
| Total Current Assets | 522.29M | 446.43M | 432.48M | 744.83M | 708.66M |
| Property, Plant & Equipment (Net) | 8.25M | 6.38M | 8.85M | 7.49M | 15.16M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.52M | 3.5M | 7.6M | 7.85M | 14.54M |
| Total Non-current Assets | 11.76M | 9.88M | 16.45M | 15.33M | 29.7M |
| Total Assets | 534.05M | 456.31M | 448.94M | 760.16M | 738.36M |
| Account Payables | 3.24M | 1.53M | 2.3M | 1.47M | 5.02M |
| Short-term Debt | 0 | 0 | 0 | 2.61M | 0 |
| Tax Payables | 0 | 0 | 0 | 2.06M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 24.27M | 48.98M |
| Other Current Liabilities | 7.92M | 10.3M | 13.15M | 17.51M | 22.37M |
| Total Current Liabilities | 22.46M | 24.06M | 35.26M | 78.71M | 116.97M |
| Long-term Debt | 0 | 9.16M | 9.33M | 6.92M | 9.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 253.91M | 424.91M |
| Other Non-current Liabilities | 375K | 265K | 705K | 1.8M | 3.16M |
| Total Non-current Liabilities | 4.99M | 11.97M | 16.4M | 267.81M | 447.25M |
| Total Liabilities | 27.44M | 36.03M | 51.66M | 346.52M | 564.23M |
| Common Stock | 7K | 7K | 7K | 8K | 9K |
| Retained Earnings | (432.97M) | (568.81M) | (721.44M) | (895.42M) | (1.17B) |
| Accumulated OCI | (1.79M) | (8.03M) | (1.27M) | 764K | 1.02M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 506.61M | 420.28M | 397.27M | 413.64M | 174.14M |
| Total Debt | 6.88M | 14.02M | 17.2M | 16.59M | 20.46M |
| Net Debt | (83.8M) | (37.78M) | (20.12M) | (207.87M) | (128.64M) |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.